OBJECTIVE： To provide reference for rational use of leucocyte increasing drugs in patients with lung cancer. METHODS： The application of drugs in lung cancer patients in 40 d each year were collected from 11 Zhejiang hospitals during 2009-2014， and then analyzed retrospectively in consumption sum， DDDs， DDC and department distribution， etc. RESULTS： The proportion of consumption sum of leucocyte increasing drugs in total consumption sum decreased generally in 11 Zhejiang hospital during 2009-2014， decreasing from 781 995.50 yuan in 2009 （3.28％） to 626 792.80 yuan in 2014 （1.53％）. Top 3 departments in the list of consumption sum of leucocyte increasing drugs were oncology department （29.00％）， radiotherapy department （27.08％） and respiratory medicine department （9.93％）. Top 3 drugs in the list of consumption sum during 2009-2014 were recombinant human granulocyte colony-stimulating factor， Coenzyme complex for injection and Leucogen tablets； top 3 drugs in the list of DDDs were Leucogen tablets， Berbamine tablet and recombinant human granulocyte colony-stimulating factor； Coenzyme complex for injection， recombinant human granulocyte colony-stimulating factor and human GM-CSF took the first three place in the list of DDC during 2009-2013， and Leucogen tablets were the top one in 2014. CONCLUSIONS： The application of leucocyte increasing drugs in lung cancer patients is decreasing year by year in 11 Zhejiang hospitals， and those with definite therapeutic efficacy and moderate price predominate clinical application predominate in the clinical practive.